Dr. Jian Wang is the Division Manager of Clinical Evaluation Division – Radiopharmaceuticals/Haematology (CED-RH). He manages a team of scientific, clinical and medical evaluators responsible for pre-market assessment of scientific and clinical data. His division has regulatory responsibility for assessing non-clinical, pharmacology and clinical data for biological drugs, including gene therapies and biosimilars, for the treatment of haematological, oncological, and infectious diseases. The Division also regulates radiopharmaceuticals (for all indications). Dr. Wang has broad regulatory experience in pre-market drug regulations for generics, biologics, biosimilars and radiopharmaceuticals. He joined the Health Canada Pesticide Management Regulatory Agency in 1996. He started working for the Therapeutic Products Directorate (TPD) in early 1999. Then in 2001, Dr. Wang moved to BRDD. He actively participates in various Health Canada, ICH, WHO and DIA working groups and expert committees.
Dr. Wang has received his medical degree in China and his PhD from the University of British Columbia in Canada.